Seeking Alpha

Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III...

Pharmacyclics (PCYC +1.7%) gets a bump higher this morning after announcing its Phase III clinical trial using Ibrutinib versus Chlorambucil to treat chronic lymphocytic leukemia and small lymphocyctic lymphoma has enrolled its fifth patient. The enrollment subsequently triggers a fourth $50M milestone payment obligation from JNJ's Janssen Biotech, who is collaborating with PCYC on Ibrutinib in oncology. On Monday, the drug was granted a 3rd "Breakthrough Therapy Designation" by the FDA.
Comments (1)
  • A SMARTER GREEK
    , contributor
    Comments (16) | Send Message
     
    Mr. Duggan the COB and CEO is doing it again witth PCYC! He did it with ISRG from 12 to over $500.00 and changed the robotic surgery industry and he is doing it again in the Oncology industry. We need more guys like him.
    11 Apr 2013, 10:38 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|